Dysfunctional Uterine Bleeding Clinical Trial
Official title:
Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized
In this study, the investigators would like to see if giving medroxyprogesterone acetate for 3 weeks after Leuprolide acetate injection will help to decrease this amount of bleeding, decrease the amount of nausea, bloating and cramping and increase patient satisfaction
Gonadotrophin releasing hormone is a decapeptide produced in the hypothalamus that
stimulates both follicle stimulating hormone and lutenizing hormone secretion from the
anterior pituitary in response to a number of endocrine feedback loops that include
estradiol, progesterone, and inhibin. Leuprolide acetate is a synthetic decapeptide and a
potent gonadrotropin-releasing hormone agonist that can be used in a number of clinical
conditions such as endometriosis, chronic pelvic pain, uterine leiomyomas, adenomyosis,
central precocious puberty and in-vitro fertilization.
This agonist is more potent that the natural gonadotrophin releasing hormone peptide as it
has a stronger affinity for the receptor and also has a longer half-life. Following
administration the high levels of gonadrotropin-releasing hormone agonist produce an
immediate increase in pituitary luteinizing hormone and follicle stimulating hormone
secretion ('flare-up'), which leads to an increase in serum estradiol within 2 days of
administration However, unlike the physiological state, where gonadotrophin releasing
hormone is produced in a pulsatile fashion, the tonically elevated levels of
gonadrotropin-releasing hormone agonist will cause a downregulation of pituitary receptors
and desensitization of the pituitary gonadotrophs which leads to a hypogonadotropic state by
the fourth week post injection. This suppression is the basis for the clinical application
of this drug in gynecology. With the initial 'flare-up', however, there can be an episode of
uterovaginal bleeding secondary to the endometrial impact of the temporary, self limited,
high circulating levels of estradiol. that appear to in the second week. This bleeding can
especially be a cause for concern in women who are already anemic at baseline.
A suggested approach for reducing or preventing this flare-related bleeding is the
administration of a progestin or estrogen-progestin combination preparation in conjunction
with the initiation of gonadrotropin-releasing hormone agonist therapy. The putative role of
the progestin is to reduce the responsiveness of the endometrium to estradiol by
downregulating endometrial estrogen receptors. Such an approach could mitigate the impact of
the estradiol flare thereby reducing the volume of the flare-related bleeding, or,
potentially, eliminate it altogether. However, a systematic review of published literature
fails to identify any studies evaluating methods designed to reduce bleeding associated with
the gonadrotropin-releasing hormone flare. The databases searched included the Cochrane
Database of Systematic Reviews as well MEDLINE using the PubMed search engine. Search words
and phrases included: gonadrotropin-releasing hormone agonist, bleeding,
gonadrotropin-releasing hormone agonist flare progestin, and leuprolide acetate. The current
instructions for use from the FDA for approved gonadrotropin-releasing hormone agonist
compounds such as leuprolide acetate do not recommend or mandate the use of progestins with
the use of gonadrotropin-releasing hormone agonist. The standard of care at this time,
therefore, is that progestins or estrogen-progestin compounds are not used when initiating
gonadrotropin-releasing hormone agonist therapy. As a result it seems appropriate to perform
structured investigation of the role of progestin-based regimens for the mitigation of
gonadrotropin-releasing hormone agonist-induced flare bleeding.
The proposed project is a pilot randomized trial to be performed in selected
gonadrotropin-releasing hormone agonist-naieve women who are initiating
gonadrotropin-releasing hormone agonist therapy with leuprolide acetate 11.25 mg as
determined by their clinicians. The study group will be randomized into one of two arms:
Those receiving medroxyprogesterone acetate administered orally in a dose of 20 mg twice
daily for the first three weeks after their first leuprolide acetate injection and the
"control" group, who receive no progestin therapy. Medroxyprogesterone acetate was selected
because it is FDA-approved for abnormal uterine bleeding, it is in widespread use and is
well tolerated, and there are multiple studies describing the use of dosages higher than
those proposed for this study. One such study was performed and published by our group
evaluating daily doses of medroxyprogesterone acetate as high as 60 mg for the treatment of
acute uterine bleeding in nongravid patients. If the investigators are able to demonstrate
that the use of medroxyprogesterone acetate significantly reduces or eliminates the volume
of uterine bleeding associated with the initiation of gonadrotropin-releasing hormone
agonist therapy, women in the KP system and elsewhere may be spared this side effect of
treatment. Such a finding may have special value for women who are already anemic and,
consequently, unable to tolerate a treatment associated bleed.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04528108 -
Chinese Medicine Periodic Therapy for Dysfunctional Uterine Bleeding During Adolescence With Yin Deficiency and Blood Heat Syndrome
|
Phase 2 | |
Completed |
NCT04428684 -
COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg
|
Phase 1 | |
Recruiting |
NCT00549159 -
CavatermTM vs TCRE in Women With DUB
|
Phase 4 | |
Not yet recruiting |
NCT04579965 -
Misotac vs Combined Oral Contraceptive Pill in the Treatment of Symptomatic Isthmocele
|
N/A | |
Terminated |
NCT01581905 -
Study of Conventional Laparoscopic Hysterectomy Versus Robot-Assisted Laparoscopic Hysterectomy at a Teaching Institution
|
N/A | |
Completed |
NCT02326922 -
The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding
|
Phase 1/Phase 2 | |
Recruiting |
NCT04396483 -
Dysfunctional Uterine Bleeding After Tubal Sterilization
|
N/A | |
Completed |
NCT01628432 -
Effect of Salpingectomy During Conservative Hysterectomy
|
N/A | |
Completed |
NCT01148420 -
DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding
|
Phase 4 | |
Completed |
NCT01173965 -
Endometrial Ablation With Non-hysteroscopic Methods
|
Phase 4 | |
Active, not recruiting |
NCT02103764 -
Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB
|
Phase 3 | |
Not yet recruiting |
NCT04290013 -
Effects of Tranexemic Acid Versus Norethisterone Acetate on Endometrial Vasculature .
|
Phase 3 |